ARTBIO: Funding, Investors & Team (Sep 2026)
ARTBIO is a company in the clinical stage of development that specializes in radiopharmaceutical biotechnology. They are dedicated to developing a novel category of alpha radioligand drugs that aim to revolutionize cancer treatment. ARTBIO is transforming the landscape of cancer care by introducing a new class of alpha radioligand therapeutics (ART) and the infrastructure to facilitate their use.
ARTBIO has raised $155M across 2 funding rounds on record, the most recent a Series B of $132M announced in Jul 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ARTBIO Company Profile and Key Stats
Latest funding round on record: Jul 2025.
ARTBIO Funding Rounds
ARTBIO raised $23.0M in a Seed announced in Jun 2023.
2.1 years later, a Series B of $132M was announced in Jul 2025.
ARTBIO Founders and Leadership Team
Contact details for the ARTBIO team: 1 of 2 have an email address on file.
Start 14-day free trial →ARTBIO Funding Compared to Other Biotechnology Startups
ARTBIO's latest round of $132M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ARTBIO in Biotechnology and Cambridge
Companies Similar to ARTBIO
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
ARTBIO Funding FAQs
What does ARTBIO do?
ARTBIO is a company in the clinical stage of development that specializes in radiopharmaceutical biotechnology. They are dedicated to developing a novel category of alpha radioligand drugs that aim to revolutionize cancer treatment. ARTBIO is transforming the landscape of cancer care by introducing a new class of alpha radioligand therapeutics (ART) and the infrastructure to facilitate their use.
How much funding has ARTBIO raised?
ARTBIO has raised $155M across 2 rounds on record. The most recent is a Series B of $132M announced in Jul 2025.
When did ARTBIO last raise funding?
ARTBIO's most recent funding round on record is a Series B of $132M, announced in Jul 2025.
Who founded ARTBIO?
FundedIQ lists Oyvind Sverre Bruland (Founder), Phil Ruis (Founder) at ARTBIO.
Where is ARTBIO headquartered?
ARTBIO is based in Cambridge, Massachusetts, United States.
How many employees does ARTBIO have?
ARTBIO is in the 51-100 employee band.
How does ARTBIO's funding compare to other Biotechnology startups?
ARTBIO's latest round of $132M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's ARTBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ARTBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.